<DOC>
	<DOCNO>NCT00003056</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . Sometimes transplanted cell make immune response body 's normal tissue . PURPOSE : Randomized phase III trial compare effectiveness cyclosporine plus methotrexate cyclosporine plus T cell depletion prevention graft-versus-host disease peripheral stem cell transplantation patient advance leukemia lymphoma eligible transplanted peripheral stem cell donor .</brief_summary>
	<brief_title>Prevention Graft-Versus-Host Disease Patients With Advanced Leukemia Lymphoma Who Are Eligible Peripheral Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : I . Demonstrate graft versus host disease ( GVHD ) prophylactic regimen consist T-cell depletion cyclosporine result less toxicity control regimen methotrexate cyclosporine recipient peripheral blood stem cell transplant . II . Monitor safety two regimen order assure treatment regimen dose result increase serious unexpected toxicity , compromise efficacy GVHD prophylaxis , compromise efficacy disease therapy . OUTLINE : This multicenter , control , randomize trial . Patients assign high low risk group randomize control treatment arm . Patients stratify risk group site . Mobilization , apheresis , successful cryopreservation minimum number CD34 cell transplant achieve prior initiate cytoreductive therapy . Following intensive cytoreductive therapy , patient receive either unselected peripheral blood stem cell ( PBSC ) together control graft versus host disease ( GVHD ) prophylaxis regimen CD34+ cell isolate PBSC cyclosporine . In control group , GVHD prophylaxis consist two drug therapy , cyclosporine methotrexate . The cyclosporine administer first IV continuous infusion later orally , twice day , decrease increment 180 day . Methotrexate administer IV day 1 , 3 , 6 , 11 . Cyclosporine discontinue day +180 evidence GVHD . In treatment group , GVHD prophylaxis consist T cell depletion transplant product use Isolex positive selection procedure ( Isolex select CD34+ cell ) cyclosporine . The cyclosporine administer dose increment control group . In case still acute chronic GVHD , patient give appropriate salvage regimen . Patients follow monthly 6 month transplant , 2 year monitor relapse . PROJECTED ACCRUAL : There 200 patient accrue ( 100 arm ) study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute lymphocytic leukemia ( ALL ) document chemosensitivity ( complete response [ CR ] , partial response [ PR ] , minor response [ MR ] ) first second remission , first second relapse , high risk ALL Ph positive 9/22 translocation ; OR Acute myelogenous leukemia ( AML ) document chemosensitivity ( CR , PR , MR ) first second remission , first second relapse ; OR Chronic myelogenous leukemia ( CML ) , chronic accelerate , blast crisis ; OR Hodgkin 's disease nonHodgkin 's lymphoma document chemosensitivity first second relapse Consenting human lymphocyte antigen ( HLA ) identical relate donor require No active central nervous system ( CNS ) skin leukemia involvement No disease require additional mediastinal radiation PATIENT CHARACTERISTICS : Age : 1855 Performance status : Karnofsky 70100 % Life expectancy : Greater 8 week Hematopoietic : Not specify Hepatic : Bilirubin le 1.5 time normal serum glutamate oxaloacetate transaminase ( SGOT ) less 2 time normal Renal : Creatinine le 1.5 time normal Cardiovascular : Left ventricular ejection fraction rest least 40 % within normal range Pulmonary : diffusing capacity lung carbon monoxide ( DLCO ) great 45 % predict within normal range Other : HIV negative At least 2 week since active infection require intravenous treatment antifungal , antibacterial antiviral agent exception coagulase negative staphylococcal line infection No coexist medical problem would significantly increase risk transplant procedure Not pregnant nursing PRIOR CONCURRENT THERAPY : No 2 prior therapy regimens Biologic therapy : No prior autologous allogeneic bone marrow peripheral blood stem cell transplant Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Prior radiation therapy subject dose requirement Surgery : Not specify Other : At least 2 week since intravenous treatment antifungal , antibacterial antiviral agent , except treatment coagulase negative staphylococcal infection IV central line</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>